Edition:
United Kingdom

People: Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

20.32USD
22 Apr 2019
Change (% chg)

$-0.56 (-2.68%)
Prev Close
$20.88
Open
$20.67
Day's High
$20.95
Day's Low
$20.12
Volume
350,492
Avg. Vol
587,292
52-wk High
$53.90
52-wk Low
$11.50

Rolfe, Lindsey 

Dr. Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM., is Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer of the Company. Dr. Rolfe joined Clovis in April 2010 and served as Senior Vice President of Clinical Development until her promotion. Dr. Rolfe has 19 years of drug development experience and previously served in senior oncology development roles at Celgene Corporation, Pharmion Corporation (acquired in 2008), Cambridge Antibody Technology, UCB Inc. and Celltech Group plc. Dr. Rolfe qualified in medicine at the University of Edinburgh. She undertook post graduate medical training in London, UK and obtained her post-graduate internal medicine qualification as a Member of the Royal College of Physicians (MRCP). She has specialist accreditation in Pharmaceutical Medicine from the UK General Medical Council and is a Fellow of the Faculty of Pharmaceutical Medicine.

Basic Compensation

Total Annual Compensation, USD 707,063
Restricted Stock Award, USD 683,100
Long-Term Incentive Plans, USD --
All Other, USD 1,039,520
Fiscal Year Total, USD 2,429,680

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 8,000 739,600.00
Name Fiscal Year Total

M. James Barrett

533,329

Patrick Mahaffy

8,726,480

Daniel Muehl

1,861,090

Gillian Ivers-Read

2,383,880

Lindsey Rolfe

2,429,680

Robert Azelby

--
As Of  31 Dec 2017